The trial compares an oral capsule of the experimental drug Lu AF28996 with a matching placebo to see if it can increase the amount of good “ON” time and reduce “OFF” time and troublesome dyskinesia. Participants will take the assigned capsule for about 19 weeks, record their daily experiences in a simple diary, and attend a few clinic visits for safety checks. The purpose is to assess whether the drug improves motor complications in people with Parkinson’s disease. In this context, “ON time” means periods when symptoms are well controlled, “OFF time” means periods when symptoms return, and “dyskinesia” refers to involuntary movements that can be bothersome.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

Participants receive a combination of oral and infused medicines that may include ribociclib, tamoxifen citrate, capecitabine, exemestane, letrozole, docetaxel, epirubicin hydrochloride, anastrozole, pembrolizumab, trastuzumab, paclitaxel, pertuzumab, carboplatin, trastuzumab emtansine, abemaciclib and cyclophosphamide monohydrate. Before and after treatment, imaging with MRI and a small tissue sample taken by image‑guided biopsy are used to check for any remaining disease, and a laboratory marker called KI67 is measured to see how the tumor is responding.

The trial begins with screening visits, followed by several cycles of the assigned medicines over a few months, after which surgery is performed. Patients are then monitored regularly for up to several years to record whether the cancer returns, to track overall health and survival, and to collect information on side effects and quality of life using simple questionnaires.

The purpose of the trial is to determine whether survodutide can lower the risk of serious liver‑related events and death in people with compensated cirrhosis due to NASH/MASH. Participants will receive the study injection each week for about a year and will attend regular clinic visits for safety checks, blood tests, and imaging. The main outcome looks at the time until the first occurrence of any major event such as liver transplant, death, hepatic decompensation (a worsening of liver function), a rise in the MELD score (a number that reflects how well the liver works) to 15 or higher, or the development of CSPH (high blood pressure in the vessels of the liver). Additional measurements include changes in the ELF score (a blood test that indicates liver scarring), body weight, blood sugar levels, and liver stiffness assessed by FibroScan (an ultrasound that measures how firm the liver is) and MRE (a type of MRI scan for the same purpose). Blood tests will also track liver enzymes AST and ALT, which rise when liver cells are damaged.

The main goal of the trial is to find out whether survodutide can improve liver health better than the placebo. “Improving liver health” means the disease may disappear without the scar tissue getting worse, and the scar tissue may become less severe. Terms such as MRI refer to a scan that uses magnets to create detailed pictures of the liver, while VCTE is a quick test that measures how stiff the liver is, which helps doctors see how much scarring is present.

Participants will receive the weekly injection for about one year and will attend regular visits where blood samples are taken, weight is measured, and imaging tests such as MRI and VCTE are performed. After the treatment period, they will continue to be followed for several more months to monitor long‑term safety and any changes in liver condition.

The purpose of the study is to find out if depemokimab works better than placebo in treating people with this lung disease who have a type of inflammation called Type 2 inflammation. The study will look at whether the medication can reduce the number of times symptoms suddenly get worse, which doctors call exacerbations. These are times when breathing problems become much worse and may need treatment with antibiotics or steroid pills, or sometimes even a visit to the emergency room or hospital.

During the study, people will receive treatment for up to 104 weeks, which is about two years. The doctors will check how often breathing problems get worse, how long it takes before problems get worse, and how the disease affects daily life and breathing symptoms. The study will compare results between people receiving depemokimab and those receiving placebo to see if the medication helps reduce flare-ups and improves quality of life for people with this lung condition.

The purpose is to determine whether the monthly treatment can achieve greater weight loss than the placebo over a period of about 72 weeks. Participants are randomly assigned to receive either the medication at one of several dose levels or the placebo, and neither the participants nor the study staff know which is administered. Injections are given every four weeks, and participants attend regular clinic visits where their weight, waist size, blood pressure, and physical function are measured.

The main goal is to evaluate the long‑term safety and tolerability of the drug. After enrollment, participants will continue taking the tablet for up to one year, returning for regular check‑ins where doctors will look for any side effects and will assess lung function using a test called FEV1, which measures how much air can be exhaled forcefully in one second. Symptom control will be measured with a short questionnaire known as the ACQ-5, and overall quality of life related to asthma will be evaluated with the AQLQ(S) questionnaire. These visits help ensure participants are monitored closely while remaining on the study medication.

During the study, participants have regular check‑ups that include blood tests, a scan called MRI (which creates detailed pictures of internal organs) to measure spleen and liver size, and assessments of blood‑carrying protein (hemoglobin) and tiny blood‑clotting cells (platelet count). A questionnaire that looks at everyday skills and motor abilities is also completed. Blood samples are taken to measure substances that indicate disease activity, and any side effects or safety concerns are recorded throughout the study period.

The purpose of the study is to find out if the under‑skin injection works at least as well as the vein infusion in terms of how the drug moves through the body (pharmacokinetic). Participants are randomly assigned to one of the two ways of receiving the medicine and will visit the clinic regularly for blood tests, imaging scans to see the tumor, and safety checks. The trial lasts for several months, during which any side effects are recorded and managed.

The main goal is to see if the drug can bring the level of cortisol measured in urine back to normal. The trial is double‑blind, meaning neither the participants nor the doctors know who gets the real medicine, and it lasts about 30 weeks. People are randomly assigned to one of the two groups and take a tablet each day.

During the study, participants will provide urine samples to measure urinary‑free cortisol, have their blood pressure checked regularly, and may undergo a sugar‑drink test (OGTT) to look at how their body handles glucose. These checks help researchers understand how well the treatment works and whether any side effects appear. The study involves several clinic visits, simple tests, and daily medication taken at home.

The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

Participants will receive an intravenous infusion of a new medicine called Imzokitug together with Pumitamig and a chemotherapy regimen known as Platinum-Doublet Chemotherapy. The chemotherapy uses two platinum‑based drugs that work by damaging the DNA of cancer cells, making it harder for them to grow. In the comparison group, patients will receive only Pumitamig and the same chemotherapy without the experimental drug. All medicines are given through a vein, usually every few weeks, and doctors will watch for side effects such as nausea, fatigue, or changes in blood counts.

The purpose of the trial is to see whether adding the experimental drug improves the proportion of patients whose tumors shrink or disappear, a measure called the objective response rate. Throughout the study, doctors will measure tumor size with imaging scans and evaluate the changes using criteria called RECIST, which provide a standard way to decide if a tumor has gotten smaller, stayed the same, or grown. Participants will be followed for several months after treatment to track how long any tumor shrinkage lasts, how long they stay without disease worsening, and overall survival, while safety is continually monitored.

The purpose of the study is to compare how well the two different treatment sequences work in slowing disease and extending survival. Participants are randomly assigned to receive either a combination of two immune drugs together, or an immune drug followed by a TKI, with a second TKI given if the cancer progresses. The study follows each person from the start of treatment, includes regular doctor visits, imaging scans evaluated by RECIST criteria, and blood tests, and continues until the disease gets worse or side effects require stopping the medication.

Throughout the trial, researchers record any side effects using the standard grading system called CTCAE, and also track overall health and quality of life. Key outcomes that will be measured are the time until the cancer progresses a second time, known as PFS-2, and overall survival, referred to as OS. The collected information helps determine which treatment approach may be more beneficial for patients with this advanced kidney cancer.

Participants in the study will take an oral tablet. Some will receive different doses of KT-621, while others will receive a placebo. To ensure the results are fair, the study is double blind, meaning neither the participants nor the researchers know which specific treatment is being administered at any given time. The study is organized into different groups that receive their assigned medication simultaneously to compare how well the drug works and to monitor its safety profile.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Durvalumab and are still benefiting from it, according to their doctor. The study will monitor the safety and how well patients tolerate the treatment. In addition to Durvalumab, the study may also involve other medications such as Infliximab and Mycophenolate Mofetil, which are used for different purposes. Infliximab is administered through an infusion, while Mycophenolate Mofetil is taken orally in capsule form.

Participants in this study will continue to receive their treatment as long as they are benefiting from it. The study will keep track of any serious side effects that occur up to 90 days after the last dose of the study treatment. This trial aims to ensure that patients who are doing well on their current treatment can continue to receive it safely.

The purpose of the study is to see whether this approach reduces the chance of the cancer coming back in the abdomen or nearby areas. After surgery, patients will be monitored with regular physical checks, blood tests, and imaging scans such as computed tomography performed with and without contrast every four months for up to three years. The follow‑up schedule also records any serious complications or deaths that occur shortly after the operation.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The purpose of the study is to see if GSK6042981 works better than sunitinib malate in slowing down the growth of the cancer or stopping it from getting worse. Patients taking part in this study will be randomly assigned to receive either GSK6042981 or sunitinib malate, and both groups will know which medicine they are receiving. During the study, doctors will monitor how well the treatment is working and how long patients can go without their disease getting worse. Patients will also be asked about their quality of life and any side effects they may experience.

Throughout the study, doctors will collect tissue samples from tumors for laboratory testing, which may come from previously stored tissue or from a new biopsy. The study will also measure the levels of GSK6042981 in the blood and track various aspects of patient health, including how long patients live, how quickly the tumor responds to treatment, and whether the cancer gets worse after starting a different treatment following the study medicine. Patients will complete questionnaires about their symptoms and overall well-being to help researchers understand how the treatments affect daily life.

The purpose of the study is to find out whether the spray can improve the sharpness of vision, known as visual acuity, compared with the placebo. Over several months, participants will use the spray daily and attend regular visits where standard eye tests are performed, such as reading letters on a chart, checking the area that can be seen without moving the eyes (visual field), and an eye scan called optical coherence tomography that measures the thickness of retinal layers. The study follows each person from the start of treatment through the end of the observation period to see how vision changes over time.

The purpose of the trial is to see whether the targeted plan reduces early infections caused by these resistant bacteria. Participants will be assigned to receive either the targeted or the standard regimen during the peri‑operative period, and they will be monitored through a series of visits up to 90 days after transplantation to record any infections, side effects, and overall health outcomes.

The purpose of the study is to learn how safe the new drug is and whether it can improve outcomes when used before surgery (called neoadjuvant therapy), after surgery (called adjuvant therapy), or as extra treatment after the main therapy (called consolidation therapy). In the first part, participants receive the new drug combined with the chemotherapy drugs before any surgery to see if the tumor shrinks enough to allow an operation and to monitor side effects. In the second part, the new drug is given by itself after surgery to check safety and tolerance, and in the third part it is given after the main treatment to see if it can be safely added. Participants receive the medication by infusion, have regular check‑ups, may undergo surgery if it becomes possible, and are followed over time to watch for any health problems.

The purpose of the study is to evaluate the safety and tolerability of S241656 when used alone and, optionally, when combined with posaconazole in the listed blood cancers. Participants will receive the study drug for several treatment cycles, with regular check‑ups that include physical examinations, laboratory tests, and monitoring for any side effects. In the optional part of the trial, participants will also take the antifungal medication for a short period to see how it influences the study drug. The trial follows a step‑wise design that starts with a low dose and may increase it if safety criteria are met, and participants may continue treatment as long as it remains safe and they choose to remain in the study.

The purpose of the trial is to determine whether the new medicine works as well as, or better than, the standard treatment in patients who have not received prior therapy for this condition. This phase 3 investigation uses a randomized, open-label design, meaning participants are assigned by chance to one of the two drugs and both the study team and participants know which drug is being taken. After enrollment, participants receive daily medication and attend regular clinic visits for safety checks and imaging scans that monitor the tumor. The study follows each person until the cancer shows signs of worsening, which is measured as progression-free survival, or until side effects require stopping the medication.

The purpose of the study is to determine whether the new drug can keep the cancer from growing for a longer time than the usual chemotherapy options. Participants are randomly placed into one of two groups, meaning the assignment is made by chance rather than choice, and receive either the oral tablets of the test drug or one of the IV chemotherapy choices selected by the doctor. Treatment cycles are given every few weeks, and patients undergo regular blood tests, imaging scans, and symptom checks to track how the disease behaves.

The study continues until the cancer shows signs of getting worse, known as progression, or until side effects become too severe to keep treatment safe. Side effects are any unwanted changes in health that may occur because of the medication, and they are closely monitored by the medical team. Throughout the trial, participants receive standard supportive care to help manage any symptoms related to the disease or its treatment.

The study looks at two treatment options. One group receives a combination of an intravenous medicine named AK104 and an oral pill called Lenvatinib. AK104 is a laboratory‑made protein that helps the body’s immune system recognize and attack cancer cells. Lenvatinib is a tablet that blocks signals that tumors use to grow and form new blood vessels. The other group receives only Lenvatinib tablets.

The purpose of the study is to compare how well the combination therapy works versus the single drug in shrinking tumors. Participants are assigned at random to one of the two groups and will take the assigned medication for several months, with regular doctor visits, blood tests, and imaging scans to watch the cancer’s response and check for side effects.

The purpose of the study is to determine whether the nerve‑block procedure can stop the dangerous heart rhythms more effectively than the standard drug treatment during the first three hours after it is given.

Participants who are experiencing an electrical storm are randomly assigned to receive either the nerve block or the intravenous medication. After the treatment, they are monitored for at least three hours to see if the abnormal beats are fully suppressed, and further observation continues for a short period to assess safety and any additional effects.

Participants are randomly assigned to receive either the study drug or placebo on a regular schedule for several months. Throughout the trial, blood tests are performed to measure thyroid hormones (such as T3, T4, and TSH) and antibodies that affect the thyroid (TRAb). Researchers also monitor overall health, side effects, and quality of life using questionnaires. The study follows participants for up to 24 weeks to see how many can maintain normal thyroid function without antithyroid drugs and to assess any safety concerns associated with the treatment.

This is an open‑label, phase 3 study, meaning that both doctors and participants know which medicines are being given and the research is at an advanced stage. After giving informed consent, participants are randomly assigned—by chance—to receive either the new combination or one of the standard combinations, and they take the pills daily. Throughout the study, participants have regular doctor visits and simple scans to check the size of the cancer, and they report any side effects, while the overall health and quality of life are also monitored over several months.

The study aims to see whether a short course of the two‑medicine DAPT for one month, followed by only ticagrelor alone, can lower the chance of net adverse clinical events compared with the standard six‑month two‑medicine plan that includes clopidogrel. Participants will be assigned to one of the two treatment paths, take the assigned pills as directed, and have a series of routine visits over the next six months to check their health and any bleeding, which will be graded using the BARC system.

During the visits, simple checks such as blood pressure, heart rhythm, and brief questionnaires will be done, and any problems will be recorded. The study follows each person for at least six months to collect information on heart‑related events, bleeding, and overall well‑being.

The purpose of the study is to see whether switching to this injection regimen keeps the virus suppressed as well as continuing the usual oral pills. Participants will receive the injection at the start of the study and then every six months, while regular clinic visits will collect blood samples to check the amount of virus, the number of CD4+ T‑cells (a type of immune cell that helps fight infections), and any changes in health over about two years.

Throughout the trial, safety will be closely watched. Any side effects or problems will be recorded, and participants may stop the study medication if serious issues arise. Blood tests will also measure how much of the new drugs remain in the body and whether the body develops any antibodies against them.

The purpose of the study is to see whether switching to the antibody‑plus‑capsid‑inhibitor regimen keeps the virus suppressed as well as the standard long‑acting injectables. Participants will receive their assigned injections or tablets on a set schedule for about two years, with regular clinic visits to check health, simple blood tests, and any side effects.

After an initial screening, participants start the assigned treatment, receive the first dose in the clinic, and then return at predetermined intervals for repeat doses and basic blood checks. Throughout the study, doctors will watch for common side effects and will measure immune cell numbers to ensure safety.

The purpose of the study is to confirm that MH002 can reduce disease activity. Participants will be randomly assigned to one of the three groups, will not know which they receive, and will be followed for about three months. During this time they will have regular visits for a colon camera exam (used to calculate the Mayo endoscopic subscore), stool tests for fecal calprotectin, and will fill out a short symptom questionnaire called PRO-2. Safety will be monitored by checking for side effects and routine lab tests.

The purpose of the study is to determine whether the experimental drug, alone or together with the blood‑vessel‑blocking drug, can improve overall survival compared with the standard pill combination plus the blood‑vessel‑blocking drug.

Participants are randomly placed into one of three groups: one group receives the experimental drug alone, a second group receives the experimental drug combined with the blood‑vessel‑blocking drug, and a third group receives the standard pill combination together with the blood‑vessel‑blocking drug. Treatments are given in repeated cycles, and participants have regular clinic visits for check‑ups, blood tests, imaging scans, and monitoring for side effects. The study continues until the disease progresses or the treatment can no longer be tolerated.